Cardiac morbidity in advanced chronic myelogenous leukaemia patients treated by successive allogeneic stem cell transplantation with busulphan/cyclophosphamide conditioning after imatinib mesylate administration

Imatinib mesylate is useful for facilitating allogeneic stem cell transplantation (allo‐SCT) in advanced‐phase chronic myelogenous leukaemia (AP‐CML) patients. However, although the side‐effects of imatinib are usually minor, cardiac morbidity can develop as a latent adverse effect post SCT when a m...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2003-05, Vol.121 (3), p.469-472
Main Authors: Sohn, Sang Kyun, Kim, Jong Gwang, Kim, Dong Hwan, Lee, Kyu Bo
Format: Article
Language:English
Subjects:
Adult
allogeneic
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Benzamides
Biological and medical sciences
Busulfan - therapeutic use
Cardiomegaly - diagnostic imaging
Cardiomegaly - etiology
chronic myelogenous leukaemia
Cyclophosphamide - therapeutic use
Drug toxicity and drugs side effects treatment
Echocardiography, Doppler
Electrocardiography
Hematology
Humans
Imatinib Mesylate
Immunosuppressive Agents - therapeutic use
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnostic imaging
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - surgery
Lung - diagnostic imaging
Male
Medical sciences
Pharmacology. Drug treatments
Piperazines - adverse effects
Piperazines - therapeutic use
Pyrimidines - adverse effects
Pyrimidines - therapeutic use
Radiography
Reoperation
Stem Cell Transplantation - adverse effects
Toxicity: cardiovascular system
Transplantation Conditioning - methods
Transplantation, Homologous
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Imatinib mesylate is useful for facilitating allogeneic stem cell transplantation (allo‐SCT) in advanced‐phase chronic myelogenous leukaemia (AP‐CML) patients. However, although the side‐effects of imatinib are usually minor, cardiac morbidity can develop as a latent adverse effect post SCT when a myeloablative SCT is given to patients taking imatinib. Two AP‐CML patients who were treated with imatinib manifested severe cardiac dysfunction after an allo‐SCT, whereas cardiac morbidity was not observed in 45 other patients who had not received imatinib. It would appear that exposure to imatinib may have an adverse impact on the heart in AP‐CML patients who receive an allo‐SCT conditioned with busulphan/cyclophosphamide.
ISSN:0007-1048
1365-2141
DOI:10.1046/j.1365-2141.2003.04288.x